OMA Guidelines Bundle

Obesity Pharmacotherapy - OMA Obesity Algorithm 2023

Obesity Medicine Association OMA GUIDELINES App Bundle brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1349812

Contents of this Issue

Navigation

Page 28 of 29

29 Weight Loss Supplements Considered Potentially Unsafe by the FDA Intervention Side Effects Mechanism of Action Sibutramine b Headache, anxiety, dry mouth, insomnia, myocardial infarction and stroke Monoamine reuptake inhibitor, increasing norepinephrine, serotonin and dopamine concentrations in the synaptic clefts and suppressing hunger. Sibutramine was removed f rom the market as an anti-obesity pharmaceutical in 2010. a Potentially unsafe when synephrine content is higher than recommended daily limits, and when combined with caffeine or unsafe and undeclared synthetic ingredients. b Some herbal "weight loss pills" are banned by the FDA due to sibutramine as an active component. e results of a clinical trial demonstrated prescription sibutramine increased myocardial infarction and stroke. Despite FDA warnings of the dangers of sibutramine, sibutramine can still be found as a "hidden ingredient" in weight loss supplements. Weight Loss Therapies with Mandated Disclaimer by the FDA Intervention Proposed Mechanism of Action Effects Warnings HCG Marketed as reducing appetite and preserving muscle mass during administration of very low calorie diet. Meta-analyses do not support clinically significant weight loss. Since 1976, the FDA has mandated a disclaimer for those who administer HCG. a In 2016, the American Medical Association passed policy that "The use of HCG for weight loss is inappropriate." a 1976 FDA disclaimer for HCG: "ere is no substantial evidence that HCG increases weight loss beyond that resulting om caloric restriction, that it causes a more attractive or normal distribution of fat, or that it decreases the hunger and discomfort associated with calorie restrictive diets." (cont'd)

Articles in this issue

Archives of this issue

view archives of OMA Guidelines Bundle - Obesity Pharmacotherapy - OMA Obesity Algorithm 2023